The annual Conference on Retroviruses and Opportunistic Infections (CROI) is the premier HIV conference in the world and draws delegates from all over the globe. This year it is being held in Boston.
Dr. Ian McGowan – Chief Scientific Officer, Orion Biotechnology – will be presenting the results of the CHARM-03 Phase 1 microbicide study which evaluated the safety and ex vivo efficacy of the CCR5 antagonist maraviroc for HIV prevention. The study is unique because it included both oral and topical maraviroc exposure. The CHARM-03 study emphasizes the importance of CCR5 antagonists in HIV prevention and this study contributed in part, to Orion Biotechnology’s focus on their potent CCR5 antagonist (5P12 RANTES) as a microbicide candidate.